CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 67 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03572738
NCT03572738N/ACompleted

Hidradenitis Suppurativa Mail Survey

Wake Forest University Health Sciences·observational·Posted Jun 28, 2018·Updated Nov 26, 2025

In Brief

An observational study for Hidradenitis Suppurativa. Completed, enrolled 67 participants across 1 site.

Detailed Summary

Hidradenitis Suppurativa (HS), also known as "acne inversa," is a chronic dermatologic disease affecting apocrine gland-bearing areas and presenting with symptoms ranging from pustules and inflammatory nodules to draining sinuses, abscesses, and fistulae. The pain and odorous lesions associated with HS contribute to its heightened impact on quality of life in comparison to other diseases; it has been described as "one of the most distressing conditions observed in dermatology." Though it is clear that HS has a significant impact on quality of life, how this manifests remains poorly characterized. The aim of this study is to characterize the quality of life impact of HS and to validate a tool for patients to self-assess the severity of their condition.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJun 28, 2018
Enrollment StartMay 14, 2018
Primary CompletionJun 30, 2020
Study CompletionJan 22, 2025
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.0 years ago